Compare Coursera Inc (COUR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Coursera Inc trades at $5.28 (market cap $1.35B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 56.6× Coursera Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Coursera Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| COUR | REGN | |
|---|---|---|
Market Cap | $1.35B | $76.40B |
Volume | 5,442,629 | 626,381 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $852.03 |
52-Week Low | $4.64 | $557.73 |
Typical Hold Time | 47 Days | 107 Days |
Enterprise Value | $606.18M | $71.12B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.27, up 2.93% with a bearish technical signal despite recent earnings beats. Revenue growth is solid (2025: $758M, 2026: $885M projected) but profitability remains negative with a -15.39% net margin. Analyst consensus is bullish with a $7.40 price target (52.94% buy ratings), while institutional activity shows mixed positioning amid Project Helix AI platform developments.
The stock offers upside potential from AI-driven growth and margin improvements, but faces execution risks on profitability and integration costs. High RSI near 82 suggests overbought conditions, while persistent net losses and competitive pressures in edtech warrant caution for near-term volatility.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
